Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Arrowhead (ARWR) deal
Tweet Send to a Friend
Mizuho analyst Uy Ear reiterated an Outperform rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst commented: "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
